Adaptimmune Therapeutics PLC Files 8-K on Executive Changes
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 8-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $473,800 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, financials
Related Tickers: ADAP
TL;DR
Adaptimmune filed an 8-K on 8/15/25 covering exec changes and financials.
AI Summary
Adaptimmune Therapeutics PLC filed an 8-K on August 15, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
FAQ
What specific executive positions were affected by the reported departures or appointments?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not specify the exact positions in the provided text.
Are there any details regarding the compensatory arrangements for the officers mentioned?
The filing lists "Compensatory Arrangements of Certain Officers" as an item of information, but the specific details of these arrangements are not included in the provided text.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This indicates that the company is providing updated financial information and supporting documentation as part of this report.
When was Adaptimmune Therapeutics PLC incorporated, and in which jurisdiction?
Adaptimmune Therapeutics PLC was incorporated in England and Wales.
What is the Standard Industrial Classification (SIC) code for Adaptimmune Therapeutics PLC?
The SIC code for Adaptimmune Therapeutics PLC is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 737 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2025-08-15 16:30:10
Key Financial Figures
- $473,800 — base salary for 2025, in the amount of $473,800, less all applicable deductions and wit
Filing Documents
- adap-20250815x8k.htm (8-K) — 38KB
- adap-20250815xex10d1.htm (EX-10.1) — 41KB
- 0001558370-25-011616.txt ( ) — 201KB
- adap-20250815.xsd (EX-101.SCH) — 4KB
- adap-20250815_lab.xml (EX-101.LAB) — 16KB
- adap-20250815_pre.xml (EX-101.PRE) — 11KB
- adap-20250815x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 10.1 Separation Agreement dated as of August 15, 2025 by and between Adaptimmune, LLC and Cintia Piccina. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date: August 15, 2025 By: /s/ Margaret Henry Name: Margaret Henry Title: Corporate Secretary